HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00518323

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Researchers compared Paliperidone ER and placebo to find out how the approaches affected psychotic symptoms in young people with schizophrenia.

Medication studyAges 12–17Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Paliperidone ER and placebo to find out how the approaches affected psychotic symptoms in young people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 12 years to 17 years. Other eligibility criteria applied.

Listed locations
Cerritos and 33 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateAugust 2007
Recruitment status
Completed
Enrollment listed in the registry
201
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, India, Romania, ...
Age range
From 12 Years to 17 Years
Official registry ID
NCT00518323
Official title
Show the full official title

A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Cerritos, United States · Fountain Valley, United States · San Diego, United States

32 more locations
  • Santa Ana, United States
  • Washington D.C., United States
  • Lake Charles, United States
  • Boston, United States
  • Cleveland, United States
  • Portsmouth, United States
  • Spokane, United States
  • Bangalore, India
  • Chennai, India
  • Hyderabad, India
  • Hyderabad Andra Pradesh, India
  • Mangalore, India
  • New Delhi, India
  • Varanasi, India
  • Bucharest, Romania
  • Ekaterinburg Na, Russia
  • Kazan', Russia
  • Moscow, Russia
  • Moscow Russia, Russia
  • Nizhny Novgorod, Russia
  • Saint Petersburg, Russia
  • Saratov, Russia
  • Smolensk Region N/A, Russia
  • Stavropol Na, Russia
  • Tomsk Na, Russia
  • Yaroslavl, Russia
  • Hlevakha, Ukraine
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Odesa, Ukraine
  • Simferopol, Ukraine
  • Russia
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Paliperidone ER and placebo to find out how the approaches affected psychotic symptoms in young people with schizophrenia.

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone ER and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 12 years to 17 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies